In support of this observation, three clinical trials (NCT01928576, NCT02437136, NCT02697630) report that entinostat was successfully administrated in combination with anti-PD-1 antibodies (pembrolizumab or nivolumab) in patients with high TMB that had progressed on or after PD-1/PD-L1 inhibitors such metastatic non-small-cell lung cancer and uveal melanoma [74–76]. This evidence concerns the gene CD274 and uveal melanoma.